On Day Two of 2024's LSX World Congress, we’ll hear about the biotech/biopharma IPO market, the 2024 US Presidential election, and about the future of digital health.
Executives from AstraZeneca, Takeda, Merck, Roche, Johnson & Johnson, Bayer, Teva, Otsuka, and Lilly will all weigh in throughout the day.
Digitalisation is happening all around us, including in tech-enabled clinical research and development.
At LSX in Boston last month, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at Astellas Pharmaceuticals to talk a bit about the company and some r
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
In this issue, we delve into the transformative impact of AI on healthcare and pharma, featuring insights on key AI trends from the floor of Frontiers Health, the ongoing battle against drift, and
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
hubXchange invites you to participate in its highly-anticipated San Diego Series 2025, a series of focused, high-level roundtable events designed to address key challenges and innovations across th
With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics.
